KathleenBMullinMD

Neurology • Stamford, CT

Headache

Neurology at Mount Sinai

Join to view full profile

Dr. Mullin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mullin's full profile

Already have an account?

Office
30 Buxton Farm Rd
Ste 230
Stamford, CT 06905
Phone+1 203-914-1900

Fax+1 203-914-1903

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2008 - 2011
Westchester Medical CenterInternship, Internal Medicine, 2007 - 2008
New York University School of MedicineClass of 2007

Certifications & Licensure

CT State Medical License 2018 - 2025
NY State Medical License 2008 - 2025
American Board of Psychiatry and Neurology Neurology
United Council for Neurologic SubspecialtiesHeadache Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
Kathleen Mullin, Robert Croop, Linda Mosher, Terence Fullerton, Jennifer Madonia
Cephalalgia. 2024-08-01
2 citations
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
Richard B Lipton, Jessica Ailani, Kathleen Mullin, Jelena M Pavlovic, Stewart J Tepper
Headache. 2024-07-03
12 citations
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry
Cephalalgia. 2024-04-01

Lectures

Headache in Children: Identification and Management
Icahn School of Medicine at Mount Sinai, New York, New York - 4/20/2013

Press Mentions

Zavzpret (Zavegepant) Migraine Nasal Spray from Pfizer Gets FDA NodMarch 14th, 2023
Migraine Nasal Spray from Pfizer Snags FDA Approval for Expected Summer LaunchMarch 11th, 2023
FDA Approves a New Nasal Spray to Treat MigrainesMarch 10th, 2023
Join now to see all